TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 32346686
Drug: 5 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg ZOL with calcium carbonate (control)
Study: 34363831
Drug: Valacyclovir (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valacyclovir (2 g immediate dose followed by 500 mg, twice a day, for 3 days) + Amoxicillin (1 g immediate dose followed by 500 mg, 4 times a day, for 7 days)
Study: 34363831
Drug: Amoxicillin (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin (1 g immediate dose followed by 500 mg, 4 times a day, for 7 days) + Placebo
Study: 36416302
Drug: Proposed model
Normalized name: Propoven
DrugBank: Propofol (DB00818)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Proposed model for assessing treatment effect heterogeneity over exposure time
Study: 36416302
Drug: Permutation test
Normalized name: mumps skin test antigen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permutation test for the variance component of the heterogeneous treatment effect parameters
Study: 36039009
Drug: solution-focussed education
Normalized name: reductic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution-focussed education and counselling
Study: 34531878
Drug: Janus kinase
Normalized name: Janus kinase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Janus kinase (JAK) inhibitors for acute and chronic graft‐versus‐host disease (GVHD) and cytokine release syndrome (CRS)
Study: 34531878
Drug: Janus kinase
Normalized name: Janus kinase inhibitor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Janus kinase (JAK) inhibitors
Study: 34887529
Drug: 10 mg/10
Normalized name: bisacodyl 10 mg/10 mL RECTAL ENEMA (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg/10 mg OLZ/SAM for 21 days
Study: 34887529
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg olanzapine for 21 days
Study: 33685474
Drug: Melatonin soft
Approvals — FDA: no, EMA: no, PMDA: no
Description: Melatonin soft gelatin capsule (5 mg twice a day for 7 days) along with standard treatment for COVID-19.
Study: 33685474
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment for COVID-19 based on the Iranian Ministry of Health and Medical Education’s protocol for 7 days.
Study: 34898011
Drug: Self-monitoring and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-monitoring and feedback (SM+FB) with access to a customized smartphone application providing three daily feedback messages.
Study: 33711941
Drug: Personalized Hypertension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalized Hypertension Management (PHMA) intervention package including support for self-monitoring, supervised machine communications, daily education or reminder messages, weekly blood pressure notification, and quarterly signed feedback.
Study: 35768902
Drug: 81 mg
Normalized name: aspirin 81 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 81 mg non-enteric coated aspirin for 1 week (NYU cohort)
Study: 35768902
Drug: 81 mg
Normalized name: aspirin 81 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 81 mg non-enteric coated aspirin for 4 weeks (Duke cohort)
Study: 35768902
Drug: 325 mg
Normalized name: lysine 325 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 325 mg non-enteric coated aspirin for 4 weeks (Duke cohort)
Study: 35768902
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of 81 mg and 325 mg non-enteric coated aspirin (Duke cohort)
Study: 38249987
Drug: Oral probiotic
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral probiotic
Study: 35906990
Drug: Extended pre-quit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended pre-quit varenicline treatment
Study: 35906990
Drug: Standard pre-quit
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pre-quit varenicline treatment
Study: 36512069
Drug: Sivopixant 150
Normalized name: Sivopixant
DrugBank: Sivopixant (DB18816)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sivopixant 150 mg
Study: 34119469
Drug: Therapy withdrawal
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy withdrawal
Study: 34119469
Drug: Control (continued
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (continued therapy)
Study: 35623995
Drug: Minimalist hypnotic
Normalized name: Synotic
DrugBank: Fluocinolone acetonide (DB00591)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Minimalist hypnotic music with guided relaxation breathing (MHMGRB) (Group II, n=40)
Study: 32723722
Drug: Virtual reality
Normalized name: RelieVRx Virtual Reality Behavioral Therapy for Pain Relief
Approvals — FDA: no, EMA: no, PMDA: no
Description: Virtual reality mindful exposure therapy (VR-MET) sessions, daily surveys, and online peer-to-peer support for 21 days.
Study: 34291584
Drug: Insulin degludec/aspart
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insulin degludec/aspart (IDegAsp)
Study: 34291584
Drug: Basal insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Basal insulin (control)
Study: 34818588
Drug: Smoking cessation
Normalized name: Zyban 150 MG Smoking Cessation 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Smoking cessation intervention (motivational interviewing sessions, 2 weeks of nicotine replacement therapy)
Study: 33719579
Drug: Naproxen (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naproxen (500 mg twice daily for 7 days)
Study: 33719579
Drug: Placebo (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (7 days of treatment)
Study: 33235447
Drug: Aerosol-inhaled amikacin
Normalized name: amikacin Inhalation Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aerosol-inhaled amikacin
Study: 35305906
Drug: Paclitaxel-Coated Balloon
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel-Coated Balloon (PCB) (SeQuent Please, B. Braun Melsungen; 3 μg/mm2)
Study: 35305906
Drug: Sirolimus-Coated Balloon
Normalized name: Sirolimus
DrugBank: Sirolimus (DB00877)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Sirolimus-Coated Balloon (SCB) (SeQuent SCB, B. Braun Melsungen; 4 μg/mm2)
Study: 33026766
Drug: Hydrogen peroxide
Normalized name: Hydrogen Peroxide
DrugBank: Hydrogen peroxide (DB11091)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hydrogen peroxide topical solution, 45% (HP45)
Study: 34529025
Drug: Carfilzomib, Lenalidomide,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carfilzomib, Lenalidomide, and Dexamethasone (KRd) followed by Lenalidomide maintenance therapy
Study: 33874968
Drug: Yarrow liver
Normalized name: YARROW
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yarrow liver compresses applied externally once daily during radiation therapy (RT)
Study: 33874968
Drug: Palliative radiation
Normalized name: allantoin
DrugBank: Allantoin (DB11100)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Palliative radiation therapy (RT) alone
Study: 35820664
Drug: Oral fluid
Normalized name: cascara sagrada ORAL FLUID EXTRACT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral fluid HIV self-test
Study: 33506314
Drug: Oral calcifediol
Normalized name: Calcifediol
DrugBank: Calcifediol (DB00146)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcifediol 20 µg/day
Study: 33506314
Drug: Oral calcifediol
Normalized name: Calcifediol
DrugBank: Calcifediol (DB00146)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral calcifediol 30 µg/day
Study: 35809362
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (TE2)
Study: 32390168
Drug: ICI monotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI monotherapy (nivolumab: 44.3%, pembrolizumab: 11.7%, ipilimumab: 23.6%)
Study: 32390168
Drug: ICI combination
Approvals — FDA: no, EMA: no, PMDA: no
Description: ICI combination therapy
Study: 32699287
Drug: Hydrogen-rich water
Normalized name: Hydrogen
DrugBank: Hydrogen (DB15127)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydrogen-rich water (HW) 1.5 L/d for 4 weeks
Study: 32565465
Drug: Lactobacillus plantarum
Normalized name: Lactobacillus Plantarum
DrugBank: Lactobacillus plantarum (DB11360)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus plantarum 299v probiotic therapy in addition to usual care
Study: 33528922
Drug: Dexmedetomidine (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexmedetomidine (0.2 to 1.5 μg/kg/hour)
Study: 33528922
Drug: Propofol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (5 to 50 μg/kg/min)
Study: 32299733
Drug: G-Series media
Normalized name: Stellaria media extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-Series media system with antioxidants (A3 group)
Study: 32299733
Drug: G-Series media
Normalized name: Stellaria media extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: G-Series media system (control)
Study: 35404772
Drug: Interruption of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interruption of sedatives
Study: 33970327
Drug: Cocoa flavanols
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cocoa flavanols (CF) 400 mg for 7 days
Study: 37194813
Drug: Standard injection
Normalized name: Stangard
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Standard injection technique
Study: 33959750
Drug: Inoculant (INO)
Normalized name: Fusisporium inosculans
DrugBank: Tilletia caries (DB10705)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inoculant (INO) containing Lactobacillus buchneri and Pediococcus pentosaceus (4 × 10^5 and 1 × 10^5 cfu/g of fresh corn)
Study: 36229117
Drug: Both treatments
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both treatments (iSOMA guided and iSOMA-GoD)
Study: 34237458
Drug: Experimental placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Experimental placebo manipulations (e.g., positive expectations, time spent with subjects, training for accurate symptom reporting)
Study: 32000687
Drug: Both LC
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both LC and CC
Study: 33917922
Drug: Standard antiplatelet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard antiplatelet therapy
Study: 36326471
Drug: Prazosin (0.05
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prazosin (0.05 mg/kg)
Study: 32041632
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D deficient children (serum 25(OH)D < 12 ng/ml)
Study: 32041632
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D inadequate children (serum 25(OH)D 12-20 ng/ml)
Study: 32041632
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D sufficient children (serum 25(OH)D > 20 ng/ml)
Study: 34429160
Drug: Tofacitinib 5
Normalized name: tofacitinib 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 5 mg BID + MTX
Study: 34429160
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg every other week + MTX
Study: 35289857
Drug: Tumor necrosis
Normalized name: Tumor necrosis factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tumor necrosis factor inhibitors (TNFis) for at least 12 weeks
Study: 34385272
Drug: BI 1265162
Normalized name: BI 2536
DrugBank: BI 2536 (DB16107)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BI 1265162 200 µg twice daily
Study: 32892245
Drug: Double-spin prepared
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Double-spin prepared PRP injection
Study: 32892245
Drug: Single-spin prepared
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-spin prepared PRP injection
Study: 32660025
Drug: Multi-strain probiotic
Normalized name: Digestive Advantage Multi-Strain Probiotic Ultra Gummies
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multi-strain probiotic (L. plantarum, L. bulgaricus, L. gasseri, B. breve, B. animalis sbsp. lactis, B. bifidum, S. thermophilus, and S. boulardii)
Study: 33739404
Drug: Rd-R (lenalidomide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rd-R (lenalidomide 10 mg per day without dexamethasone)
Study: 35546664
Drug: GLP-1 receptor
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: GLP-1 receptor agonists (albiglutide, exenatide, liraglutide, semaglutide, lixisenatide, dulaglutide)
Study: 32375735
Drug: Primary surgery
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary surgery followed by systemic therapy
Study: 32375735
Drug: Primary systemic
Normalized name: Sodium primary phosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Primary systemic therapy without surgery
Study: 36378077
Drug: 150iu BD
Normalized name: BD
DrugBank: Butylene glycol (DB14110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 150iu BD of formulated regular insulin in enteric-coated capsules
Study: 36378077
Drug: 75iu BD
Normalized name: BD
DrugBank: Butylene glycol (DB14110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 75iu BD of formulated regular insulin in enteric-coated capsules
Study: 36378077
Drug: 300iu BD
Normalized name: BD
DrugBank: Butylene glycol (DB14110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300iu BD of formulated regular insulin in enteric-coated capsules
Study: 35758031
Drug: Mirabegron (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirabegron (300 mg daily)
Study: 34136900
Drug: STIMULAX (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: STIMULAX (oral Coloxyl® with senna and macrogol, with sodium phosphate enema for right-sided operations)
Study: 35544473
Drug: Lipid/insulin infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lipid/insulin infusion
Study: 32464224
Drug: Higher-volume feedings
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Higher-volume feedings (180-200 mL/kg/d)
Study: 32464224
Drug: Usual-volume feedings
Normalized name: SET,FEEDING
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual-volume feedings (140-160 mL/kg/d)
Study: 35898121
Drug: Standard of
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of care (topical numbing cream, positioning, and distraction by games on tablet/smartphone)
Study: 34561291
Drug: Biomarker-directed treatment
Normalized name: direct blue 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Biomarker-directed treatment adjustment
Study: 34561291
Drug: Transition onto
Normalized name: Ontosein
DrugBank: Orgotein (DB11444)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transition onto or off oral corticosteroids
Study: 34561291
Drug: Prior study
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior study medication changes (two or more changes)
Study: 33412106
Drug: FF/UMEC/VI 200/31·25/25
Approvals — FDA: no, EMA: no, PMDA: no
Description: FF/UMEC/VI 200/31·25/25 μg
Study: 32203980
Drug: Deferasirox dispersible
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferasirox dispersible tablets (10 to 40 mg/kg per day)
Study: 32798567
Drug: High early
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High early parenteral soybean oil lipid intake starting at 2 g/kg per day, increasing to 3 g/kg per day the following day.
Study: 32798567
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group started at 0.5-1 g/kg per day, increasing daily by 0.5-1 g/kg per day till reaching 3 g/kg per day.
Study: 34220819
Drug: Haemophilus influenzae‐type
Approvals — FDA: no, EMA: no, PMDA: no
Description: Haemophilus influenzae‐type b (Hib) vaccine
Study: 33227803
Drug: Daily probiotic
Normalized name: CVS Daily Probiotic Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily probiotic milk (once daily)
Study: 36447243
Drug: High-dose ECV19
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose ECV19 (20 μg RBD)
Study: 36447243
Drug: Low-dose ECV19
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose ECV19 (10 μg RBD)
Study: 35449351
Drug: Clinical pharmacist-led
Normalized name: DuoCare Clinical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clinical pharmacist-led stewardship program for appropriate use of acid suppression therapy
Study: 32242396
Drug: Lingqi Huangban
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lingqi Huangban granule (LQHB) plus intravitreal ranibizumab (IVR) injections
Study: 34504129
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with optic nerve damage before treatment
Study: 36327345
Drug: Computer based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Computer based cognitive therapy (CBCT)
Study: 36091012
Drug: Mepolizumab (300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mepolizumab (300 mg, subcutaneous, every 4 weeks)
Study: 34698726
Drug: Short antibiotic
Normalized name: short ragweed pollen extract Sublingual Tablet [Ragwitek]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short antibiotic prophylaxis (24 hours)
Study: 34698726
Drug: Extended antibiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Extended antibiotic prophylaxis (7 days)
Study: 36330836
Drug: Control arm
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Control arm (four weeks of weekly questionnaires)
Study: 32384147
Drug: Arginine therapy
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine therapy (100 mg/kg IV 3 times/day)
Study: 32384147
Drug: Arginine therapy
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine therapy (loading dose 200 mg/kg then 100 mg/kg TID)
Study: 32384147
Drug: Arginine therapy
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine therapy (loading dose 200 mg/kg followed by continuous infusion 300 mg/kg per day)
Study: 32384147
Drug: Arginine therapy
Normalized name: Arginine
DrugBank: Arginine (DB00125)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Arginine therapy (all doses)
Study: 34797272
Drug: Yoga-based cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yoga-based cognitive behavioral therapy (Y-CBT)
Study: 34474163
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of ST2 and REG3α
Study: 35698203
Drug: Dexmedetomidine (DEX)
DrugBank: Dexmedetomidine (DB00633)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dexmedetomidine (DEX) group - loading dose of 1 μg/kg for 15 min and continuous infusion at 0.6 μg/kg/h until 30 min before the end of operation.
Study: 35698203
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group - normal saline infusion.
Study: 35162346
Drug: 4 mL
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL of plain 0.5% ropivacaine with perineurally added 1 mL/4 mg of dexamethasone (Group I)
Study: 35162346
Drug: 4 mL
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL of plain 0.5% ropivacaine with perineurally added 1 mL of 0.9% saline (Group II)
Study: 35162346
Drug: 4 mL
Normalized name: ethanol 1.4 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 mL of plain 0.5% bupivacaine with perineurally added 1 mL of 0.9% saline (Group III)
Study: 35934082
Drug: REGN1908/1909 600
Approvals — FDA: no, EMA: no, PMDA: no
Description: REGN1908/1909 600 mg
Study: 34935603
Drug: VR training
Normalized name: Prostin VR
DrugBank: Alprostadil (DB00770)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: VR training along with conventional physical therapy (CPT)
Study: 36008108
Drug: Vitamin D
Normalized name: Vitamin D
DrugBank: Vitamin D (DB11094)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vitamin D treatment (50,000 IU bi-weekly)
Study: 34798706
Drug: QLB-LSAL with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: QLB-LSAL with 0.5% ropivacaine (25 mL)
Study: 34798706
Drug: TQLB with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: TQLB with 0.5% ropivacaine (25 mL)
Study: 33831611
Drug: Microsurgical treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microsurgical treatment (MST)
Study: 32084522
Drug: High-dose spatially
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-dose spatially fractionated radiation therapy (12 to 14 Gy via dose cylinders)
Study: 32084522
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment (external beam radiation therapy to the entire prostate and proximal seminal vesicles to 76 Gy at 2 Gy/fraction)
Study: 34256607
Drug: Gabapentin (1,200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gabapentin (1,200 mg/day)
Study: 34460904
Drug: Antibiotic Stewardship
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antibiotic Stewardship Rounds (ASRs)
Study: 34033975
Drug: Tislelizumab plus
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab plus chemotherapy (platinum and pemetrexed)
Study: 34033975
Drug: Chemotherapy alone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy alone (platinum and pemetrexed)
Study: 39738721
Drug: Tislelizumab plus
Normalized name: Tislelizumab
DrugBank: Tislelizumab (DB14922)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tislelizumab plus chemotherapy
Study: 35653758
Drug: Hearing emotion
Normalized name: carbamide peroxide
DrugBank: Carbamide peroxide (DB11129)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hearing emotion labels before sorting (e.g., 'happy faces go here')
Study: 35653758
Drug: Not given
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not given labels (e.g., 'faces like this go here')
Study: 33536102
Drug: Simvastatin (10-20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (10-20 mg/day)
Study: 33536102
Drug: Captopril (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Captopril (0.2 mg/kg/day)
Study: 35037116
Drug: Berberine (900
Approvals — FDA: no, EMA: no, PMDA: no
Description: Berberine (900 mg/day)
Study: 32746774
Drug: 200g of
Normalized name: Oil of peppermint
DrugBank: Peppermint oil (DB11198)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200g of cod twice a week for 16 weeks
Study: 33253318
Drug: Baseline visceral-to-subcutaneous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline visceral-to-subcutaneous fat ratio (VFR)
Study: 35404227
Drug: Propranolol administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol administered orally 60 to 75 minutes prior to psychotherapeutic sessions
Study: 33831625
Drug: Surgical dressing
Normalized name: SURGICAL DRESSINGS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Surgical dressing changed twice a week (HMO)
Study: 33105353
Drug: β-Alanine (12
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-Alanine (12 g/d for 14 days)